OrbiMed declares 12.3% of Aspen Neuroscience after its IPO, for investment only
OrbiMed, a healthcare investor, holds 12.3% of newly listed Aspen Neuroscience, and says it bought the shares as an investment, not to take control.
The filing
13D
12.3%
Of the shares
$46.8M
Value
Active
Investor
A
Aspen Neuroscience, Inc. Common Stock
Holds 3,589,132 shares
Stated purpose
OrbiMed says it holds Aspen Neuroscience shares as an investment, not to gain control, and will review the holding and may buy or sell later.
Declared to the SEC, the US stock market watchdog (Schedule 13D), after the 5% threshold was crossed on November 2, filed on November 6.
AI analysis
Nov 6
With TrueWallet Pro
What this filing changes for the stock, what the fund wants, and what it does not say. Upgrade to Pro from the TrueWallet app.